N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.
暂无分享,去创建一个
Robert R Luedtke | Amy Hauck Newman | D. Sibley | A. Newman | Y. Mishra | R. Luedtke | Ashwini K Banala | Benjamin A Levy | Sameer S Khatri | Cheryse A Furman | Rebecca A Roof | Yogesh Mishra | Suzy A Griffin | David R Sibley | A. Banala | Cheryse A. Furman | S. Griffin | R. Roof | Benjamin Levy
[1] R. Spealman,et al. Dopamine D3 and D2 Receptor Mechanisms in the Abuse-Related Behavioral Effects of Cocaine: Studies with Preferential Antagonists in Squirrel Monkeys , 2010, Journal of Pharmacology and Experimental Therapeutics.
[2] R. Mach,et al. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl carbamate analogs as σ2 receptor ligands , 2006 .
[3] Robert R Luedtke,et al. Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SAR. , 2007, Bioorganic & medicinal chemistry letters.
[4] Erin E. Carlson,et al. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. , 2005, Journal of medicinal chemistry.
[5] Gebhard F. X. Schertler,et al. Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.
[6] J. Ballesteros,et al. The first transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. , 2000, Biochemistry.
[7] Robert H Mach,et al. Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. , 2005, Bioorganic & medicinal chemistry.
[8] R. Mach,et al. Evaluation of D2 and D3 dopamine receptor selective compounds on l-dopa-dependent abnormal involuntary movements in rats , 2009, Neuropharmacology.
[9] Peter Gmeiner,et al. The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects. , 2006, Pharmacology & therapeutics.
[10] A. Newman,et al. Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders , 2010, Annals of the New York Academy of Sciences.
[11] A. Newman,et al. Dopamine D3 Receptors Mediate the Discriminative Stimulus Effects of Quinpirole in Free-Feeding Rats , 2010, Journal of Pharmacology and Experimental Therapeutics.
[12] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[13] J. Hagan,et al. 1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: A Series of Potent and Selective Dopamine D3 Receptor Antagonists , 2007 .
[14] Francesca Zazzeroni,et al. The Tetrahydroisoquinoline Derivative SB269,652 Is an Allosteric Antagonist at Dopamine D3 and D2 Receptors , 2010, Molecular Pharmacology.
[15] J. Palacios,et al. Visualization of dopamine D1, D2 and D3 receptor mRNA's in human and rat brain , 1992, Neurochemistry International.
[16] M. Reith,et al. Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action. , 2008, Journal of medicinal chemistry.
[17] R. Stevens,et al. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.
[18] M. Millan,et al. Dopamine D3 receptor antagonists as therapeutic agents. , 2005, Drug discovery today.
[19] Lei Shi,et al. The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[20] Susanta K. Sarkar,et al. Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists , 2010, Psychopharmacology.
[21] A. Capelli,et al. 1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists. , 2010, Journal of medicinal chemistry.
[22] Jonathan A. Javitch,et al. Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.
[23] R. Mach,et al. Characterization of 125I‐IABN, a novel azabicyclononane benzamide selective for D2‐like dopamine receptors , 2000, Synapse.
[24] K. Neve,et al. Structural Determinants of Pharmacological Specificity Between D1 and D2 Dopamine Receptors , 2006, Molecular Pharmacology.
[25] Bernardo L. Sabatini,et al. Competitive regulation of synaptic Ca influx by D2 dopamine and A2A adenosine receptors , 2010, Nature Neuroscience.
[26] R. Mach,et al. Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. , 2010, Bioorganic & medicinal chemistry.
[27] G. Koob,et al. PRECLINICAL STUDY: FULL ARTICLE: The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended‐access , 2010, Addiction biology.
[28] Harald Hübner,et al. Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding. , 2009, Journal of medicinal chemistry.
[29] A. Newman,et al. Dopamine Agonist-Induced Yawning in Rats: A Dopamine D3 Receptor-Mediated Behavior , 2005, Journal of Pharmacology and Experimental Therapeutics.
[30] Ji-Kyung Choi,et al. Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. , 2007, Journal of medicinal chemistry.
[31] Robert R Luedtke,et al. N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. , 2009, Journal of medicinal chemistry.